Morgan Stanley Aeglea Bio Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.11 - $0.46 $1,138 - $4,761	-10,350 Reduced 75.79%	3,306 $1,000
Q1 2023 May 15, 2023	SELL	$0.29 - $0.61 $19,373 - $40,751	-66,805 Reduced 83.03%	13,656 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.35 - $1.54 $30,728 - $135,207	-87,797 Reduced 52.18%	80,461 $36,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $47,718 - $101,716	-125,576 Reduced 42.74%	168,258 $88,000
Q2 2022 Oct 27, 2022	BUY	$0.5 - $2.66 $56,066 - $298,273	112,133 Added 61.71%	293,834 $148,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $56,066 - $298,273	112,133 Added 61.71%	293,834 $148,000
Q1 2022 Oct 27, 2022	SELL	$1.87 - $4.77 $209,688 - $534,874	-112,133 Reduced 38.16%	181,701 $418,000
Q1 2022 May 13, 2022	SELL	$1.87 - $4.77 $27,146 - $69,246	-14,517 Reduced 7.4%	181,701 $418,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $6,975 - $16,781	1,993 Added 1.03%	196,218 $932,000
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $1.17 Million - $1.54 Million	194,225 New	194,225 $1.54 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.